Cabaletta Bio Inc (CABA)
10.17
+0.24
(+2.42%)
USD |
NASDAQ |
May 31, 16:00
10.17
0.00 (0.00%)
After-Hours: 20:00
Cabaletta Bio Research and Development Expense (Quarterly): 21.95M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 21.95M |
| December 31, 2023 | 17.40M |
| September 30, 2023 | 13.79M |
| June 30, 2023 | 11.80M |
| March 31, 2023 | 12.44M |
| December 31, 2022 | 12.40M |
| September 30, 2022 | 8.216M |
| June 30, 2022 | 9.514M |
| March 31, 2022 | 9.17M |
| December 31, 2021 | 9.919M |
| September 30, 2021 | 8.169M |
| June 30, 2021 | 7.85M |
| Date | Value |
|---|---|
| March 31, 2021 | 6.556M |
| December 31, 2020 | 5.775M |
| September 30, 2020 | 5.65M |
| June 30, 2020 | 5.331M |
| March 31, 2020 | 4.62M |
| December 31, 2019 | 3.026M |
| September 30, 2019 | 3.22M |
| June 30, 2019 | 2.664M |
| March 31, 2019 | 2.761M |
| December 31, 2018 | 1.239M |
| September 30, 2018 | 2.589M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.664M
Minimum
Jun 2019
21.95M
Maximum
Mar 2024
8.973M
Average
8.192M
Median
Research and Development Expense (Quarterly) Benchmarks
| Editas Medicine Inc | 48.79M |
| ACADIA Pharmaceuticals Inc | 59.68M |
| Alnylam Pharmaceuticals Inc | 261.00M |
| Regeneron Pharmaceuticals Inc | 1.248B |
| Vertex Pharmaceuticals Inc | 789.10M |